NL7404425A - - Google Patents

Info

Publication number
NL7404425A
NL7404425A NL7404425A NL7404425A NL7404425A NL 7404425 A NL7404425 A NL 7404425A NL 7404425 A NL7404425 A NL 7404425A NL 7404425 A NL7404425 A NL 7404425A NL 7404425 A NL7404425 A NL 7404425A
Authority
NL
Netherlands
Application number
NL7404425A
Other versions
NL178967B (nl
NL178967C (nl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NL7404425A publication Critical patent/NL7404425A/xx
Publication of NL178967B publication Critical patent/NL178967B/xx
Application granted granted Critical
Publication of NL178967C publication Critical patent/NL178967C/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
NLAANVRAGE7404425,A 1973-04-02 1974-04-01 Werkwijze voor het bereiden van een geneesmiddel met antihyperlipidemische werking en van een daarvoor geschikt alkoxyarylcarbonzuur. NL178967C (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/347,064 US4110351A (en) 1973-04-02 1973-04-02 Hypolipidemic agents RO- or RS- substituted furoic acids, esters and salts

Publications (3)

Publication Number Publication Date
NL7404425A true NL7404425A (xx) 1974-10-04
NL178967B NL178967B (nl) 1986-01-16
NL178967C NL178967C (nl) 1986-06-16

Family

ID=23362171

Family Applications (1)

Application Number Title Priority Date Filing Date
NLAANVRAGE7404425,A NL178967C (nl) 1973-04-02 1974-04-01 Werkwijze voor het bereiden van een geneesmiddel met antihyperlipidemische werking en van een daarvoor geschikt alkoxyarylcarbonzuur.

Country Status (13)

Country Link
US (2) US4110351A (xx)
JP (1) JPS5844668B2 (xx)
AU (1) AU473143B2 (xx)
BE (1) BE813040A (xx)
CA (1) CA1077051A (xx)
CH (1) CH593960A5 (xx)
DE (1) DE2414680C2 (xx)
FR (1) FR2223030B1 (xx)
GB (1) GB1413648A (xx)
NL (1) NL178967C (xx)
PH (1) PH17946A (xx)
SE (1) SE417512B (xx)
ZA (1) ZA741420B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017514A (en) * 1975-06-16 1977-04-12 Richardson-Merrell Inc. Hypolipidemic agents
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
JPS621279U (xx) * 1985-06-17 1987-01-07
US4980371A (en) * 1988-12-21 1990-12-25 Merrell Dow Pharmaceuticals Antiretroviral furan ketones
US5665874A (en) * 1989-01-17 1997-09-09 John Hopkins University Cancer related antigen
US5759791A (en) * 1989-01-17 1998-06-02 The Johns Hopkins University Cancer related antigen
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6624194B1 (en) * 1999-06-04 2003-09-23 Metabolex, Inc. Use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7199259B2 (en) * 2003-06-20 2007-04-03 Metabolex, Inc. Resolution of α-(phenoxy)phenylacetic acid derivatives
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
EP1749000A4 (en) * 2004-05-25 2009-12-30 Metabolex Inc BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF
US7714131B2 (en) * 2005-09-23 2010-05-11 Metabolex, Inc. Process for the stereoselective preparation of (−)-halofenate and derivatives thereof
CA2668414C (en) * 2006-11-03 2015-02-10 Qlt Inc. Methods of treating dermatological disorders or conditions
MX2012000435A (es) * 2009-07-08 2012-06-01 Dermira Canada Inc Analogos de acido 5-(tetradeciloxi)-2-furancarboxilico (tofa) utiles en el tratamiento de trastornos o afecciones dermatologicas.
AU2013203113B2 (en) * 2009-07-08 2015-03-26 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
PL3253743T4 (pl) 2015-02-05 2020-03-31 Dermira, Inc. Syntetyczny sposób otrzymywania pochodnych kwasu 2-furanokarboksylowego
WO2019072478A1 (en) 2017-10-10 2019-04-18 Galderma Research & Development SPECIFIC ACETYL-COA CARBOXYLASE INHIBITORS FOR USE IN THE TREATMENT AND / OR PREVENTION OF ACNE
WO2024026012A1 (en) * 2022-07-29 2024-02-01 The Regents Of The University Of California Compositions and methods for treating metabolic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3517050A (en) * 1966-10-03 1970-06-23 Merck & Co Inc Ester and amide derivative of (3-trifluoromethylphenoxy) (4 - halophenyl)acetic acid
US3716644A (en) * 1971-07-15 1973-02-13 American Cyanamid Co Hypolipidemic agents

Also Published As

Publication number Publication date
JPS49127963A (xx) 1974-12-07
US4110351A (en) 1978-08-29
SE417512B (sv) 1981-03-23
DE2414680A1 (de) 1974-10-17
PH17946A (en) 1985-02-11
AU6640974A (en) 1975-09-11
NL178967B (nl) 1986-01-16
GB1413648A (en) 1975-11-12
JPS5844668B2 (ja) 1983-10-04
FR2223030B1 (xx) 1977-05-06
BE813040A (fr) 1974-07-15
US4146623A (en) 1979-03-27
FR2223030A1 (xx) 1974-10-25
DE2414680C2 (de) 1983-12-22
ZA741420B (en) 1975-01-29
AU473143B2 (en) 1976-06-17
CA1077051A (en) 1980-05-06
CH593960A5 (xx) 1977-12-30
NL178967C (nl) 1986-06-16

Similar Documents

Publication Publication Date Title
AR201758A1 (xx)
AU476761B2 (xx)
AU465372B2 (xx)
AU474593B2 (xx)
AU474511B2 (xx)
FR2223030B1 (xx)
AU474838B2 (xx)
AU465453B2 (xx)
AU471343B2 (xx)
AU465434B2 (xx)
AU450229B2 (xx)
FR2223031B1 (xx)
AU476714B2 (xx)
AU476696B2 (xx)
AU466283B2 (xx)
AU472848B2 (xx)
AU477823B2 (xx)
AU476873B1 (xx)
AR201432A1 (xx)
AR210729A1 (xx)
AU461342B2 (xx)
AU447540B2 (xx)
AU477824B2 (xx)
AU471461B2 (xx)
AU1891376A (xx)

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
A85 Still pending on 85-01-01
V1 Lapsed because of non-payment of the annual fee